Structure of class C GPCR metabotropic glutamate receptor 5 transmembrane domain

Nature

Volumn 511, Issue 7511, 2014, Pages 557-562

  Doré, Andrew S ^a   Okrasa, Krzysztof ^a   Patel, Jayesh C ^a   Serrano Vega, Maria ^a   Bennett, Kirstie ^a   Cooke, Robert M ^a   Errey, James C ^a   Jazayeri, Ali ^a   Khan, Samir ^a   Tehan, Ben ^a   Weir, Malcolm ^a   Wiggin, Giselle R ^a   Marshall, Fiona H ^a  

^a Heptares Therapeutics Ltd   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MAVOGLURANT; METABOTROPIC RECEPTOR 5;

ANIMAL CELL; ARTICLE; BINDING SITE; CONTROLLED STUDY; CRYSTAL STRUCTURE; HUMAN; HUMAN CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; REGULATORY MECHANISM; SIGNAL TRANSDUCTION; TRANSMEMBRANE DOMAIN;

AMINO ACID MOTIFS; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; HEK293 CELLS; HUMANS; MODELS, MOLECULAR; PROTEIN STRUCTURE, TERTIARY; RECEPTOR, METABOTROPIC GLUTAMATE 5; RHODOPSIN;

EID: 84904994581     PISSN: 00280836     EISSN: 14764687     Source Type: Journal    
DOI: 10.1038/nature13396     Document Type: Article

References (50)

1. Pin, J. P., Galvez, T.& Prézeau, L. Evolution, structure, and activationmechanismof family 3/C G-protein-coupled receptors. Pharmacol. Ther. 98, 325-354 (2003).
2. Shigemoto, R. et al. Immunohistochemical localization of a metabotropic glutamate receptor, mGluR5, in the rat brain. Neurosci. Lett. 163, 53-57 (1993).
3. Li, G., Jørgensen, M. & Campbell, B. M. Metabotropic glutamate receptor 5-negative allosteric modulators for the treatment of psychiatric and neurological disorders (2009-July 2013). Pharm. Pat. Anal. 2, 767-802 (2013).
4. Levenga, J. et al. AFQ056, a new mGluR5 antagonist for treatment of fragile X syndrome. Neurobiol. Dis. 42, 311-317 (2011).
5. Stauffer, S. R. Progress toward positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGlu5). ACS Chem. Neurosci. 2, 450-470 (2011).
6. Venkatakrishnan, A. J. et al. Molecular signatures of G-protein-coupled receptors. Nature 494, 185-194 (2013).
7. Rosenbaum, D. M., Rasmussen, S. G. F. & Kobilka, B. K. The structure and function of G-protein-coupled receptors. Nature 459, 356-363 (2009).
8. Katritch, V., Cherezov, V. & Stevens, R. C. Diversity and modularity of G proteincoupled receptor structures. Trends Pharmacol. Sci. 33, 17-27 (2012).
9. Wang, C. et al. Structure of the human smoothened receptor bound to an antitumour agent. Nature 497, 338-343 (2013).
10. Hollenstein, K. et al. Structure of class B GPCR corticotropin-releasing factor receptor 1. Nature 499, 438-443 (2013).
11. Siu, F. Y. et al. Structure of the human glucagon class B G-protein-coupled receptor. Nature 499, 444-449 (2013).
12. Bräuner-Osborne, H., Wellendorf, P. & Jensen, A. A. Structure, pharmacology and therapeutic prospects of family C G-protein coupled receptors. Curr. Drug Targets 8, 169-184 (2007).
13. Kunishima, N. et al. Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor. Nature 407, 971-977 (2000).
14. Tsuchiya, D., Kunishima, N., Kamiya, N., Jingami, H.& Morikawa, K. Structural views of the ligand-binding cores of a metabotropic glutamate receptor complexed with an antagonist and both glutamate and Gd31. Proc. Natl Acad. Sci. USA 99, 2660-2665 (2002).
15. Hu, J. & Spiegel, A. M. Structure and function of the human calcium-sensing receptor: insights from natural and engineered mutations and allosteric modulators. J. Cell. Mol. Med. 11, 908-922 (2007).
16. Conn, P. J., Christopoulos, A. & Lindsley, C. W. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nature Rev. Drug Discov. 8, 41-54 (2009).
17. Serrano-Vega, M. J., Magnani, F., Shibata, Y. & Tate, C. G. Conformational thermostabilization of the b1-adrenergic receptor in a detergent-resistant form. Proc. Natl Acad. Sci. USA 105, 877-882 (2008).
18. Shibata, Y. et al. Thermostabilization of the neurotensin receptorNTS1. J. Mol. Biol. 390, 262-277 (2009).
19. Lebon, G., Bennett, K., Jazayeri, A. & Tate, C. G. Thermostabilisation of an agonistbound conformation of the human adenosine A2A receptor. J. Mol. Biol. 409, 298-310 (2011).
20. Gasparini, F. et al. [(3)H]-M-MPEP, a potent, subtype-selective radioligand for the metabotropic glutamate receptor subtype 5. Bioorg.Med. Chem. Lett. 12, 407-409 (2002).
21. Ballesteros, J. A. & Weinstein, H. Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors. Methods Neurosci. 25, 366-428 (1995).
22. Fredriksson, R., Lagerström, M. C., Lundin, L. G. & Schiöth, H. B. The G-proteincoupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. Mol. Pharmacol. 63, 1256-1272 (2003).
23. Söding, J. Protein homology detection by HMM-HMM comparison. Bioinformatics 21, 951-960 (2005).
24. Goudet, C. et al. Heptahelical domain of metabotropic glutamate receptor 5 behaves like rhodopsin-like receptors. Proc. Natl Acad. Sci. USA 101, 378-383 (2004).
25. El Moustaine, D. et al. Distinct roles of metabotropic glutamate receptor dimerization in agonist activation and G protein coupling. Proc. Natl Acad. Sci. USA 109, 16342-16347 (2012).
26. Schwartz, T. W., Frimurer, T. M., Holst, B., Rosenkilde, M. M. & Elling, C. E. Molecular mechanism of 7TM receptor activation-a global toggle switch model. Annu. Rev. Pharmacol. Toxicol. 46, 481-519 (2006).
27. Hofmann, K. P. et al. A G protein-coupled receptor at work: the rhodopsin model. Trends Biochem. Sci. 34, 540-552 (2009).
28. Binet, V. et al. Common structural requirements for heptahelical domain function in class A and class C G protein-coupled receptors. J. Biol. Chem. 282, 12154-12163 (2007).
29. Chang, W., Chen, T. H., Pratt, S. & Shoback, D. Amino acids in the second and third intracellular loops of the parathyroid Ca21-sensing receptor mediate efficient coupling to phospholipase C. J. Biol. Chem. 275, 19955-19963 (2000).
30. Beqollari, D., Betzenhauser, M. J. & Kammermeier, P. J. Altered G-protein coupling in anmGluR6 pointmutant associated with congenital stationary night blindness. Mol. Pharmacol. 76, 992-997 (2009).
31. Scheerer, P. et al. Crystal structure of opsin in its G-protein-interacting conformation. Nature 455, 497-502 (2008).
32. Rasmussen, S. G. F. et al. Crystal structure of the b2 adrenergic receptor-Gs protein complex. Nature 477, 549-555 (2011).
33. Malherbe, P. et al. Mutational analysis and molecular modeling of the binding pocket of the metabotropic glutamate 5 receptor negative modulator 2-methyl-6- (phenylethynyl)-pyridine. Mol. Pharmacol. 64, 823-832 (2003).
34. Malherbe, P. et al. Comparison of the binding pockets of two chemically unrelated allosteric antagonists of themGlu5 receptor and identification of crucial residues involved in the inverse agonism of MPEP. J. Neurochem. 98, 601-615 (2006).
35. Gregory, K. J. et al. Probing the metabotropic glutamate receptor 5 (mGlu5) positive allosteric modulator (PAM) binding pocket: discovery of point mutations that engender a ''molecular switch'' in PAM pharmacology. Mol. Pharmacol. 83, 991-1006 (2013).
36. Pagano, A. et al. The non-competitive antagonists 2-methyl-6- (phenylethynyl)pyridine and 7-hydroxyiminocyclopropan[b]chromen-1acarboxylic acid ethyl ester interact with overlapping binding pockets in the transmembrane region of group Imetabotropic glutamate receptors. J. Biol. Chem. 275, 33750-33758 (2000).
37. O'Brien, J. A. et al. A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5.Mol.Pharmacol. 64, 731-740(2003).
38. Ballesteros, J. A., Deupi, X., Olivella, M., Haaksma, E. E. & Pardo, L. Serine and threonine residues bend a-helices in the x1 5 g conformation. Biophys. J. 79, 2754-2760 (2000).
39. Wu, H. et al. Structure of a class C GPCRmetabotropic glutamate receptor 1 bound to an allosteric modulator. Science 344, 58-64 (2014).
40. Robertson, N. et al.The properties of thermostabilisedGprotein- coupledreceptors (StaRs) and their use in drug discovery. Neuropharmacology 60, 36-44 (2011).
41. Kawate, T. & Gouaux, E. Fluorescence-detection size-exclusion chromatography for precrystallization screening of integral membrane proteins. Structure 14, 673-681 (2006).
42. Caffrey, M. & Cherezov, V. Crystallizing membrane proteins using lipidic mesophases. Nature Protocols 4, 706-731 (2009).
43. Kabsch, W. XDS. Acta Crystallogr. D 66, 125-132 (2010).
44. Leslie, A. G. W. & Powell, H. R. Processing diffraction data with Mosflm. Evolving Meth. Macromolecular Crystallogr. 245, 41-51 (2007).
45. Winn, M. D. et al. Overview of the CCP4 suite and current developments. Acta Crystallogr. D 67, 235-242 (2011).
46. McCoy, A. J. et al.Phaser crystallographic software. J.Appl. Crystallogr.40, 658-674 (2007).
47. Murshudov, G. N. et al. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr. D 67, 355-367 (2011).
48. Emsley, P., Lohkamp, B., Scott, W. G. & Cowtan, K. Features and development of Coot. Acta Crystallogr. D 66, 486-501 (2010).
49. Adams, P. D. et al. PHENIX: a comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D 66, 213-221 (2010).
50. Chen, V. B. et al. MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr. D 66, 12-21 (2010).